Dojolvi on the market in the U.S.: the first long-chain fatty acid oxidation metabolic disease drug!

Dojolvi is a high-purity, pharmaceutical grade, medium-chain triglycerides that connect three seven-carbon fatty acids to synthetic seven-carbon fatty acid triglycerides produced on a glycerin skeleton through a multi-step chemical process.
the drug is designed to provide patients with medium-length odd-chain fatty acids that can be metabolized in the Krebs cycle during the critical energy generation process to increase the intermediate substrate, thereby directly addressing LC-FAOD defects.
unlike typical even-chain fatty acids, an intermediate produced by Dojolvi through Krebs cycle can also be converted into new glucose, which may provide important additional therapeutic effects, especially when glucose levels are too low.
original source: Ultragenyx Announces U.S. Commercial Launch of Dojolvi ™ (Triheptanoin), the FirstFDA-approved therapy for the Treatment of the Long-Long-Chain Fatty Acid Oxidation SanIc Samen Sazzs Original Title: 20 Years of Rare Diseases! Dojolvi on the market in the U.S.: The first long-chain fatty acid oxidation metabolic disease (LC-FAOD) drug!